Podcasts about Novartis

In episode 272, Coffey talks with Amie Fox about inclusive recruitment as a skills-first strategy — and why getting disability inclusion right across the hiring lifecycle unlocks better outcomes for all types of diverse talent. – HRSOUTHWEST October 11-13, 2026 – Good Morning, HR listeners can use the promo code 2026-CoffeyGMHR-100 to save $100 on an HRSouthwest full conference registration at https://hrsouthwest.com!------------------------------------------------------------------------------------------------------------------------------------------------ They discuss inclusive recruitment defined as removing intentional and unintentional barriers so the best-skilled candidate can move through the process without obstruction; honest, specific job descriptions that reflect actual role requirements rather than aspirational proxies and that allow unqualified candidates to self-select out; disability as the inclusion starting point — with the disability community twice as likely to be unemployed as non-disabled peers despite being frequently over-educated; the average $300 cost of a reasonable accommodation in the US and available government funding through state and county workforce boards to offset it; skills-based hiring as the most equitable screening approach because it focuses on demonstrable job-relevant competencies rather than credential proxies; AI and assistive technology as equalizers for candidates and employees with disabilities, enabling participation and independence in ways previously unavailable; designing the application process intentionally — including accessibility of job postings, assessments, and office environments — to remove barriers before the interview stage; how to handle disability disclosure in interviews, ask practical accessibility questions, and kick the elephant out of the room without legal risk; the medical model versus social model of disability and why moving past fear of offense is the key to unlocking genuine inclusion conversations; and onboarding as the most critical retention tool — including pre-start communication, 90-day planning, accommodations setup before day one, and maintaining connection so new hires know where the bathroom is. Good Morning, HR is brought to you by Imperative—Bulletproof Background Checks. For more information about our commitment to quality and excellent customer service, visit us at https://imperativeinfo.com.If you are an HRCI or SHRM-certified professional, this episode of Good Morning, HR has been pre-approved for three quarters of a recertification credit. To obtain the recertification information for this episode, visit https://goodmorninghr.com.ABOUT OUR GUEST Amie Fox is the Founder of A Fox Consulting, a trainer and keynote speaker who helps founders, HR and operations leaders in growing organisations build practical people systems that improve employee engagement, manager confidence, and business performance. She moved into this work after a portfolio career across communications, training, fundraising, corporate responsibility, and operations exposed her to how differently people experience workplaces. A key turning point was struggling to find early employment as a visually impaired woman, which shaped her understanding of hidden barriers, workplace design, and the importance of systems that help people perform at their best. Her credibility is grounded in recent and current roles: she set up A Fox Consulting, serves as a non-executive director at Vision Ireland, and has held senior CSR and operations roles at organisations including SCOPE Eyecare & Healthcare. Through her consulting, communications, fundraising, and inclusion work, she has contributed to projects with organisations such as McDonald's, Telefonica, Deloitte, Novartis, Abbott, Newstalk, and John Sisk & Sons. Amie's work is built around the employee life cycle as the foundation for better people performance. She supports leaders and managers through coaching, training, and mentoring designed to maximise employee engagement and performance across each stage of that life cycle. Her book Mind the Blind Spot: Decision to Done and her FoxBuzz framework are practical manifestations of her central thesis: when people feel good, they perform at their best — but that idea only becomes useful when translated into clear routines, structures, and systems that work in boardrooms and in daily operations. Amie can be reached at:Website: www.afox.ieLinkedIn: https://www.linkedin.com/in/amie-fox-a3420333/Instagram: https://www.instagram.com/consultingafox/YouTube: https://www.youtube.com/@AFoxConsulting ABOUT MIKE COFFEY Mike Coffey is an entrepreneur, licensed private investigator, business strategist, HR consultant, and registered yoga teacher. In 1999, he founded Imperative (https://www.imperativeinfo.com/), a background investigations and due diligence firm helping risk-averse clients make well-informed decisions about the people they involve in their business. Imperative delivers in-depth employment background investigations, know-your-customer and anti-money laundering compliance, and due diligence investigations to more than 300 risk-averse corporate clients across the US, and, through its PFC Caregiver & Household Screening (https://pfcinformation.com/) brand, many more private estates, family offices, and personal service agencies. Imperative has been named a Best Places to Work, the Texas Association of Business' small business of the year, and is accredited by the Professional Background Screening Association. Mike shares his insight from 25+ years of HR-entrepreneurship on the Good Morning, HR podcast (https://goodmorninghr.com/), where each week he talks to business leaders about bringing people together to create value for all stakeholders. Mike has been recognized as an Entrepreneur of Excellence by FW, Inc. and has twice been recognized as the North Texas HR Professional of the Year. Mike serves as a board member of a number of organizations, including the Texas State Council (https://texasshrm.org/), where he serves Texas' 30 SHRM chapters as State Director-Elect; Workforce Solutions for Tarrant County (https://workforcesolutions.net/); the Texas Association of Business (https://txbiz.org/); and the Fort Worth Chamber of Commerce (https://www.fortworthchamber.com/), where he is chair of the Talent Committee. Mike is a certified Senior Professional in Human Resources (SPHR) through the HR Certification Institute and a SHRM Senior Certified Professional (SHRM-SCP). He is also a Yoga Alliance registered yoga teacher (RYT-200) and teaches multiple times each week. Mike and his very patient wife of 29 years are empty nesters in Fort Worth. LEARNING OBJECTIVES • Define inclusive recruitment as a skills-first, barrier-removal process and apply a five-stage framework — advertising reach, accessible information, application design, interview structure, and onboarding — to identify gaps in an existing hiring process. • Explain why disability inclusion serves as a foundation for broader inclusive hiring, and describe how accommodati...

Novartis made the most likable pharma ad of the Super Bowl—Gronk, hammocks, "relax your tight end"—and won the Pharma Lions Grand Prix at Cannes for it. But when paid media is the only channel that legal can fully control, the ad quietly becomes your whole operating system, and everything it can't say gets handed to someone else.  In this month's PESO Model® Diagnostic, Gini Dietrich runs the full Novartis campaign through the PESO lens, names the regulated-industry trap, and lays out the fixes that survive a compliance review—at every size of organization. Take the PESO Model® Diagnostic: https://spinsucks.com/self-peso-diagnostic/PESO Model® Certification: https://spinsucks.com/peso-model-certification/Full article: https://spinsucks.com/communication/peso-model-diagnostic-novartis/

Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL, BAFF and CD38. On the latest BioCentury This Week podcast, BioCentury's analysts assess how next-generation therapies are competing on safety and longer dosing intervals.The analysts also discuss Heidi Overton's FDA commissioner confirmation hearing and lingering questions about her independence, new pharma tariff guidance that leaves exemptions unclear, and how reverse mergers paired with nine-figure PIPEs became a viable IPO alternative. Plus, Merck's $400 million upfront bet on a preclinical KRAS G12C molecular glue.View full story: https://www.biocentury.com/article/660935#IgANephropathy #FDA #BiotechIPO #DrugDevelopment #ClinicalTrials0:00 Introduction1:30 Grand Rounds: Europe Recap6:03 IgA Nephropathy Pipeline14:57 Overton Hearing22:19 Commerce's Tariff Guidance24:28 Reverse Mergers' New LookTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

On The Kenny & JT Show we welcome in Pro Football Hall of Famer Anthony Munoz. The 1998 inductee played offensive tackle for the Cincinnati Bengals from 1980-1992. Anthony is in the community this week as part of the Hall's Residency Program presented by Novartis. Our interview is driven by Akron Auto Auction and akronautoauction.com.

By 2050, nearly half the world's population is expected to be myopic, with around a billion people projected to progress to high myopia — a leading cause of irreversible vision loss later in life. Children face a narrow window in which to intervene, while the eye is still growing, before those structural changes become permanent. Yet despite the scale of the problem, there is still no FDA-approved drug that slows myopia progression in children, a gap underscored just last month when the FDA declined to approve an atropine eye drop for the same use.My guest today is Thomas Ruggia, President and CEO of Theialife, a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite. Tom joins Theialife after 25 years in ophthalmology leadership, including roles at Johnson & Johnson, Alcon, Novartis, and most recently as CEO of Samsara Vision. We'll talk mechanism, evidence, and the road to Phase 3.01:49 Meet Thomas Ruggia06:50 How progressive myopia develops in children and why it's misunderstood15:55 ND10's mechanism of action19:51 20 years of Danish compassionate-use data vs. a randomised trial26:44 Why no FDA-approved pharmacologic therapy exists yet37:57 Theialife's pipeline beyond myopiaInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Innovation in ophthalmology: How biotechs are reshaping the treatment of eye diseasesCan gene therapy treat vision loss?Europe's Ophthalmology Scene Stays Hot for Biotech Funding

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is pulsating with advancements, strategic collaborations, regulatory approvals, and promising clinical trial results that are reshaping the landscape of healthcare and drug development. A notable collaboration making waves is between Boehringer Ingelheim and Envisagenics, a partnership valued at $1 billion. This multi-year agreement harnesses artificial intelligence in RNA splicing through the SpliceCore platform, particularly targeting oncology. This move underscores a growing trend to integrate AI and machine learning into drug discovery processes, emphasizing precise genetic interventions that could transform cancer therapies by accelerating and refining development processes. Boehringer Ingelheim's collaboration with Envisagenics marks a significant investment into oncology research using AI to identify novel tumor-specific targets. In regulatory news, Johnson & Johnson's Caplyta has achieved its primary endpoint in a Phase 3 trial focused on manic episodes associated with Bipolar I disorder. As an atypical antipsychotic, Caplyta offers a promising therapeutic option for managing this complex condition, potentially expanding treatment arsenals in neurological disorders. Further, AbbVie's Rinvoq has been approved by the European Commission for pediatric polyarticular juvenile idiopathic arthritis, marking an expansion of JAK inhibitors in treating autoimmune diseases. This approval provides much-needed hope for pediatric patients grappling with debilitating conditions. Meanwhile, Menarini Group and NewAmsterdam Pharma's cardiovascular drugs Ubeslo and Evlarco have also secured European Commission approval. These CETP inhibitors address hypercholesterolemia, offering innovative approaches in managing cholesterol levels—a key factor in cardiovascular disease risk. The business landscape is robust with key partnerships emphasizing AI-driven drug discovery. AbbVie has teamed up with Iambic Therapeutics to explore AI applications across immunology, neuroscience, and oncology. Meanwhile, Novartis has entered into a licensing deal with BoomRay Pharmaceuticals for preclinical radioligand therapy, highlighting an ongoing interest in breakthrough cancer treatments. Geographical dynamics are shifting as forecasts predict increased Western licensing deals for Chinese radioligand therapies by 2027. This trend highlights global biotech ecosystems' interconnectivity and cross-border innovation potential. In clinical trials, Otsuka and Ionis Pharmaceuticals' ulefnersen achieved its Phase 3 primary endpoint for FUS-ALS, marking progress toward FDA discussions for RNA-targeted therapies in ALS treatment. Vertex's Inaxaplin has shown positive Phase 2b results for APOL1-mediated kidney disease. Amgen's Dazodalibep met its Phase 3 endpoint by easing Sjogren's disease severity through CD40 ligand targeting. Amgen has made headway with its investigational drug for Sjogren's disease. Its Phase 3 trial success is crucial for Amgen's Horizon Therapeutics-acquired pipeline, offering new hope for patients with challenging autoimmune conditions. IPO activities are also buzzing. Iambic Therapeutics plans to advance its AI-driven HER2 inhibitor IAM1363 through an IPO, spotlighting AI's burgeoning role in oncology drug development and its potential to revolutionize personalized cancer treatment strategies. On the regulatory front, the FDA is actively pushing forward with approvals for key products. Merck's Winrevair and Nuvation's Ibtrozi are leading this wave of regulatory activity that could shift market dynamics significantly. In diabetes treatment, Roche has shown promising results with its dual GLP-1/GIP receptor agonist in a Phase 2 trial. Meeting primary endpoints presents this drug candidate as a potential best-in-disease therapy for type 2 diabetes patients who are overweight or obese. Eli Lilly's early-stage data supports its GLP-1/GIP candidate's potential beyond metabolic diseases, offering revolutionary treatment paradigms for psychiatric disorders. Challenges persist despite these scientific achievements. A survey highlights that one-third of UK women feel their migraine pain isn't taken seriously due to gender biases, emphasizing the need for more empathetic healthcare practices. Strategic acquisitions continue to shape industry dynamics. Lexeo Therapeutics' acquisition of Friedreich ataxia assets underscores commitment to rare genetic disorders. Novo Nordisk is undergoing strategic workforce reductions to bolster R&D efforts while aiming to increase oral Wegovy production capacity by 2030—a strategic focus on scaling production capabilities. These developments underscore the importance of leveraging innovative technologies and strategic collaborations to address complex health challenges. The integration of AI, expansion of manufacturing capacities, and successful clinical outcomes are pivotal in advancing patient care and optimizing drug development pathways. These strides promise transformative impacts on global health outcomes in the coming years.Support the show

The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an alternate route to NASDAQ. On the latest BioCentury This Week podcast, BioCentury's analysts examine momentum in the biotech IPO market.The team also unpacks fatal toxicities in Novartis' autoimmune CAR-T trials and what they reveal about manufacturing, dosing and immune biology risks across the modality. In Washington, Steve Usdin previews Heidi Overton's FDA Commissioner confirmation hearing and reports on the persistent uncertainty around pharma tariffs ahead of the Sept. 29 deadline.View full story: https://www.biocentury.com/article/660870#BiotechIPO #CARTCell #FDA #PharmaTariffs #DrugDevelopment0:00 Introduction02:15 Biotech IPO Market10:38 Autoimmune CAR-T Safety21:56 FDA Commissioner Hearing26:47 Pharma Tariff UncertaintyTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Ab heute sind Sandoz und Galderma im SMI vertreten – Kühne und Nagel sowie Swisscom räumen das Feld. Somit nimmt der Pharmabereich mit rund 41 Prozent an Gewicht zu. Laut Jörn Spillmann, Anlage-Experte der Zürcher Kantonalbank, bleiben Novartis, Roche und Nestlé weiterhin die grössten Treiber. SMI: +1.2%

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Frank Binder, Independent Consultant (external manufacturing and supply chain management).   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Frank, covering:   Getting hooked on supply chain management during his time at Accenture, before joining Novartis' biopharma business during the early stages of outsourcing and CDMO management. Deciding to move to Celgene, and feeling liberated by the hands-on, can-do culture of a fast growth company. The intrigue of joining a highly respected Japanese pharma company to help drive global supply chain alignment. Common themes in pharma and CDMO relationships, including better planning, clearer communication and secondary sourcing. How CDMO selection has evolved over the last 10 to 15 years, what has changed and what remains the same, including the role of regionalisation. The lens he uses to identify genuine, strategic partners he can trust.   Dr. Frank Binder is a senior supply chain leader with experience across major pharmaceutical and biopharmaceutical companies in Switzerland, the US and Japan. He is now an independent consultant at GSCA | Global Supply Chain Advisors, having previously held senior roles at Santen, Celgene, Novartis, Roche and Accenture. His expertise spans global supply chain transformation, biologics and API production, CDMO management, international logistics, planning, NPI and SOP/IBP. Frank is a recognised pharmaceutical supply chain thought leader, regularly speaking at industry conferences across Europe, the US and Asia. He holds a doctorate in Physical Chemistry from the University of Berne, with further executive education at Cranfield University, Harvard Business School and INSEAD.   Connect with him on LinkedIn.   Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Drei große Pharmafirmen haben jahrelang an einem Medikament gearbeitet, das einen neu entdeckten Risikofaktor für Herzinfarkt und Schlaganfall bekämpfen sollte. Die erste große Studie ist jetzt da – und das Ergebnis ist ernüchternd.In dieser Folge sprechen wir darüber, was Lipoprotein A ist, warum es bei 20 Prozent aller Menschen erhöht ist – und was die neue Studie wirklich bedeutet, wenn man genau hinschaut.Es geht um Morbus Mohl, Aktienkurse und Weißkittel-Hochdruck.01:34 Risikofaktoren04:55 Lipoprotein A10:40 Zu spät angesetzt?15:13 Aktienkurs20:09 Morbus Mohl

This episode covers:  The role of AI in heart failure and prevention AI advances in interventional cardiology Training cardiologists of the future Host: Fielder Camm Guests: Benjamin Meder, Pim van der Harst, Jozine ter Maaten and Mark Westwood Want to watch that episode? Go to: https://esc365.escardio.org/event/2554 Disclaimer: ESC TV Today is supported by Novartis and Novo Nordisk through independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Dan Atar, Yasmina Bououdina, Fielder Camm, Nicolle Kraenkel, Jozine Ter Maaten, Pim Van der Harst and Mark Westwood have declared to have no potential conflicts of interest to report. Carlos Aguiar has adeclared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Benjamin Meder has declared to have potential conflicts of interest to report: Alexion, Alynlam, Amgen, Apple Inc., AstraZeneca, Bayer AG, BNK, Biontech, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Daiichi Sankyo, Deutsche Gesellschaft für Kardiologie, German Center for Cardiovascular Research, German Research Foundation, Hummingbird Diagnostics, Intellia, Johnson&Johnson, Klaus-Tschira Foundation, Informatics for Life, Leducq Foundation (CASTT), Novartis, Novo Nordisk, Pfizer, SA, Sixt, SMT, Space X, Zoll. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of dynamic and significant advancements across the industry, from strategic acquisitions to regulatory shifts and scientific innovations. In a bold move, Novartis has acquired Sironax's blood-brain barrier delivery platform for $125 million. This acquisition marks a strategic enhancement in Novartis's ability to deliver therapies directly to the brain, overcoming one of the most formidable challenges in treating neurological disorders. The potential to deliver antibodies and other therapeutic agents effectively across this barrier could lead to groundbreaking treatments for conditions like Alzheimer's disease and multiple sclerosis. This reflects a broader industry trend emphasizing improved drug delivery systems to boost treatment efficacy and patient outcomes. On the clinical advancement front, Sling Therapeutics has raised $123 million in a Series C funding round aimed at propelling its oral therapy for thyroid eye disease forward. Unlike traditional intravenous treatments, this oral therapy offers a more convenient option for patients, potentially improving adherence and quality of life. Meanwhile, Circle Pharma's $92.5 million Series E funding will support the development of its cyclin D1 inhibitor for breast cancer, showcasing innovation in oncology through the use of macrocycles that could provide more effective treatments with fewer side effects. Investments in AI and machine learning are also reshaping the landscape. Ginkgo Bioworks' collaboration with Novo Nordisk to construct an autonomous lab highlights the increasing role of automation in optimizing R&D productivity. Mithrl's $20 million Series A round further underscores this shift, focusing on developing an AI infrastructure platform for streamlined biopharma drug discovery processes. The regulatory environment continues to evolve with notable challenges. BioMarin has discontinued Phase 2 development of Voxzogo in Noonan syndrome due to shifting treatment landscapes, illustrating the dynamic nature of therapeutic development. Similarly, Novartis's halt on its TREM2 stabilizer after a Phase 2 failure in ALS research points to the complexities inherent in neurodegenerative disease studies. Maat Pharma faced a setback when its appeal was rejected regarding the EMA's negative opinion on its graft-versus-host disease candidate, Xervyteg. This instance highlights the stringent regulatory hurdles companies must navigate to bring novel therapies to market. Amid these developments, Gilead Sciences is strategically expanding into oncology and inflammation. Through several acquisitions, Gilead has diversified its portfolio significantly, emphasizing oncology as a central focus area given its high potential for addressing unmet needs and offering substantial returns on investment. Legend Biotech's appointment of Ingrid Zhang as CEO signals a strategic push into the competitive CAR-T cell therapy market. These therapies represent a revolutionary approach in personalized medicine for cancer treatment, with Legend positioning itself for growth and innovation. Bristol Myers Squibb and Ono Pharmaceutical are preparing to contest Amgen's efforts to launch a biosimilar for their oncology blockbuster Opdivo. This reflects broader competitive dynamics within the biologics market where biosimilars promise more cost-effective options, potentially reshaping market shares and pricing strategies. Manufacturing innovations are also at play with Ori Biotech securing a $120 million deal for an automated production platform in cell therapy manufacturing. Such advancements are crucial as cell therapies become more mainstream, necessitating scalable solutions that maintain quality while meeting demand. Operational expansions continue as Reckitt Benckiser allocates $600 million to upgrade its US operations, fostering innovation across health and hygiene product lines—an industry trend towards integrating R&D with manufacturing prowess to drive new product development. While challenges persist—illustrated by Novartis's multiple trial failures—the pharmaceutical and biotech sectors remain resilient with adaptive strategies focused on innovation. The ongoing advancements underscore not only scientific exploration but also strategic maneuvering amidst evolving regulatory landscapes. As AI reshapes talent acquisition strategies and technological advancements accelerate drug discovery processes, companies must navigate complex global health ecosystems poised for transformative growth. The focus remains on improving patient outcomes through cutting-edge science while balancing innovation with strategic realignment. Thank you for tuning into Pharma Daily—where we keep you abreast of pivotal industry shifts shaping the future of healthcare. Join us again tomorrow as we continue exploring these exciting developments impacting patient care worldwide.Support the show

In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Jeremy Levin, a physician, scientist, biotech executive, and longtime leader in the pharmaceutical industry. Jeremy has held senior roles across Genzyme, Novartis, Bristol-Myers Squibb, and Teva, and today serves as Executive Chairman of Ovid Therapeutics. Throughout his career, he has helped shape major advances in biotechnology, from the industry's early days to the rise of immuno-oncology and new approaches to neurological disease. Jeremy traces his journey from growing up on a farm in South Africa and moving between countries as a refugee to studying at Oxford and Cambridge and eventually entering the emerging U.S. biotech industry. He explains how his training as a physician and scientist has remained central to his career and why he sees companies, capital, and strategy ultimately as tools for getting better medicines to more patients. The conversation explores defining moments in Jeremy's career, including learning the business of biotech at Genzyme and developing the “String of Pearls” strategy at Bristol-Myers Squibb. That approach helped Bristol build new capabilities in biologics and make a bold bet on immuno-oncology at a time when much of the industry remained skeptical. Jeremy also discusses returning to entrepreneurship with Ovid Therapeutics to pursue neurological diseases that much of pharma had abandoned. He reflects on clinical failure, the importance of patient organizations, and why progress often requires being willing to “put your neck on the line.” The episode closes with his perspective on the future of American biotechnology and the need to support science, innovation, and public trust to keep the next generation of breakthroughs moving forward.

Synopsis: What does it take to turn a once-fringe scientific idea into a new approach to drug discovery—and build a biotech company around it for the long haul? In this episode of Biotech 2050, host Rahul Chaturvedi sits down with Nello Mainolfi, Founder, President & CEO of Kymera Therapeutics, to explore his journey from chemist and drug hunter to biotech founder, and the decade-long evolution of Kymera into a leader in targeted protein degradation. Nello shares how scientific curiosity first drew him to protein degradation when the modality was barely known across the industry, why he believes biotech companies must “earn the right to grow,” and how Kymera made the pivotal decision to move away from oncology and concentrate its resources on immunology. He also discusses Kymera's clinical progress, including its STAT6 and IRF5 degrader programs, and the potential for oral medicines to address pathways historically targeted by injectable biologics. Beyond the science, Nello offers lessons from his evolution as a first-time founder CEO—from hiring and retaining the right people to building trust, preserving culture as an organization scales, knowing when to go deep and when to delegate, and maintaining resilience amid the constant demands of leading a public biotech company. Tune in for a conversation about scientific conviction, disciplined company building, targeted protein degradation, and why people and culture can ultimately matter as much as the technology itself. Biography: Nello is Founder, President, and Chief Executive Officer of Kymera Therapeutics. Under his leadership, Kymera has advanced a novel modality and built a pipeline of multiple clinical stage, first-in-class degrader programs across a variety of indications; developed a best-in-class drug discovery platform; raised close to $3 billion in capital and formed strategic collaborations with major biopharmaceutical companies. Nello began his career at Novartis, leading cross-functional teams that identified several novel investigational medicines including the first-in-class, FDA approved, factor B inhibitor iptacopan. Nello studied at Imperial College, University of London and The Scripps Research Institute in California and has authored more than 100 publications and patents. He is passionate about helping teams achieve what has not been done before and scaling Kymera into a leading global biopharma company.

The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its TrialBlazer initiative. Meanwhile, Definium Therapeutics notched another late-stage trial win for its LSD drug, and Novartis continues to reel from the company's triple asset stumble.

Building Consumer Brands in Eye Care. Mary Teryek, vice president of Marketing, North America Consumer, shares how Bausch + Lomb evolves its consumer eye care brands to meet shifting health and wellness expectations, and what eye care professionals can learn from modern marketing strategies.About The Guest:Mary Teryek is the vice president of Marketing, North America Consumer, at Bausch + Lomb. In this role, she leads marketing strategy and execution across the company's portfolio of over-the-counter eye care brands, including LUMIFY, Blink, Biotrue and PreserVision, as well as other eye care, lens care and eye vitamin products.  Mrs. Teryek joined Bausch + Lomb in 2017 and brings more than 20 years of experience growing consumer brands across the health, wellness, and beauty categories. Prior to joining the company, she held senior marketing leadership roles at Johnson & Johnson and Novartis, where she led brand development, innovation and consumer engagement for several iconic global brands including CeraVe and Johnson & Johnson Baby.Like this episode? Please subscribe and share!iTunes | Spotify | Overcast | iHeartRadio | AmazonConnect with the OWA:Website | LinkedIn | Instagram | Facebook

This week on Conflict Managed we welcome Amie Fox. Together we explore: The business case for disability inclusion Work systems: design with human nature and user experience in mind What do I need people to know, feel, and do after this interaction? Moving beyond compliance to see, value & recognize others Progress, not perfection Resistance as fear Feedback culture Conflict Managed is available wherever you get your podcasts and on YouTube @ 3pconflictrestoration. Amie Fox is a managing director, trainer and keynote speaker who helps founders, HR and operations leaders in growing organizations build practical people systems that improve employee engagement, manager confidence and business performance. She moved into this work after a portfolio career across communications, training, fundraising, corporate responsibility and operations exposed her to how differently people experience workplaces. A key turning point was struggling to find early employment as a visually impaired woman, which shaped her understanding of hidden barriers, workplace design and the importance of systems that help people perform at their best. Her credibility is grounded in recent and current roles: she set up A Fox Consulting, serves as a non-executive director at Vision Ireland, and has held senior CSR and operations roles at organizations including SCOPE Eyecare & Healthcare. Through her consulting, communications, fundraising and inclusion work, she has contributed to projects with organizations such as McDonald's, Telefonica, Deloitte, Novartis, Abbott, Newstalk and John Sisk & Sons. Conflict Managed is produced by Third Party Workplace Conflict Restoration Services and hosted by Merry Brown.   #ConflictManagement #WorkplaceCulture #Communication #Podcast

On this week's episode, Tess Cameron, Brian Skorney, Paul Matteis, and Yaron Werber open with a look at markets, noting the XBI slipped just over 3% amid concerns about energy prices, inflation, and long-term U.S. fiscal health weighing on the rate-sensitive sector. The conversation then turns to policy, discussing new FDA leadership appointments including Karim Mikhail as CBER director, with hosts noting the industry's hope for a calmer, less chaotic regulatory tone. They highlight the FDA's apparent openness to psychedelics, pointing to stock reactions across the space. On the data front, Novartis's pelacarsen missed expectations reducing Lp(a) relative to rival programs from Amgen and Eli Lilly, while its DM1 program also fell short, shifting attention to Dyne Therapeutics' upcoming expansion cohort data. The hosts debate whether Novartis's setbacks make early-commercial, post-Phase 3 companies more attractive acquisition targets given looming loss-of-exclusivity pressure across large pharma. In other data news, Roivant's mosliciguat hit its Phase 2 primary endpoints in interstitial lung disease, with the company already advancing to Phase 3. The episode closes with Biohaven's epilepsy trial hold pending further metabolite data, and questions over whether the hold could affect its recent SK Pharma deal. This episode aired on September 11, 2026.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. First, let's delve into the innovative work being done by Grove Biopharma. Founded in 2020 in Chicago, this company is at the forefront of developing polymer-peptide hybrids to target intracellular protein-protein interactions, areas traditionally deemed undruggable. These interactions are crucial regulatory components in numerous cellular processes and are implicated in diseases like cancer and neurodegenerative disorders. However, their smooth protein surfaces present a challenge for traditional small molecule drugs, which struggle to find suitable binding pockets. Similarly, biologics like antibodies and peptides, despite their high binding affinities, face difficulties penetrating cell membranes due to their size and instability. Grove Biopharma addresses these issues through its proprietary Bionics Biologics™ technology. Developed by Nathan Gianneschi at Northwestern University, this approach uses protein-like polymers to mimic proteins with enhanced stability and cellular penetration. These polymers, adorned with peptide branches via living polymerization, maintain peptide binding properties while overcoming previous limitations in drug delivery. This breakthrough has already shown promise in preclinical studies. A 2023 study in Science Advances revealed the efficacy of targeting membrane protein CD36 for treating macular degeneration in mice, while a 2024 study demonstrated PLPs' ability to penetrate neurons and target mitochondria in Huntington's disease models. Moreover, a 2026 Nature Communications publication introduced HYDRAC, a new PLP class capable of degrading MYC and KRAS proteins, reducing tumor growth in mice. Grove Biopharma's pipeline is robust, targeting key areas in cancer and neurodegeneration. Despite challenges typical of the biotech landscape—such as toxicity concerns during clinical trials and scalability issues—Grove's unique platform offers the flexibility needed to address multiple targets effectively. Shifting focus to industry-wide developments, recent advancements highlight significant strides in personalized medicine. Moderna and Merck's mRNA cancer vaccine has shown promising results in a phase 3 study, marking an important step forward for customized healthcare approaches based on genetic profiles. This not only offers hope for cancer treatment but also signifies a wider shift towards more tailored therapeutic strategies. Regulatory updates also play a critical role in shaping industry dynamics. The appointment of Dr. Angelo De Claro as chief of the FDA Oncology Center of Excellence is pivotal. His focus on modernizing regulatory practices aims to expedite drug approvals while ensuring that innovative treatments reach patients more swiftly. However, the FDA's decision to delay approval for Exelixis' tyrosine kinase inhibitor with Roche's Tecentriq underscores the complexities involved in novel therapies' assessments. On the geographical front, Singapore's launch of a biotech hub in Boston highlights the global nature of biotech development. This move strengthens historical ties and emphasizes international collaboration's importance in accelerating scientific research. In clinical trials, AbbVie's success with Qulipta (atogepant) for menstrual migraine prevention is noteworthy. It not only expands therapeutic options for women but also underscores a growing focus on gender-specific health issues within clinical research. Meanwhile, new RAS-targeting therapies continue to emerge as Revolution Medicines' Rasonque gains approval for advanced pancreatic cancer treatment—a significant milestone in addressing previously undruggable mutations. Industry dynamics are further illustrated by leadership changes at major firms like Takeda. The departure of long-time R&D chief Andy Plump often signals strategic shifts that could influence research priorities and corporate focus. Novartis recently faced setbacks with late-stage asset failures impacting its market position and raising investor concerns about its strategic direction concerning mergers and acquisitions. On a similar note, Takeda undergoes organizational changes amid potential strategic shifts following its CEO appointment—demonstrating volatility within companies striving for competitive advantage through effective leadership. Promising developments at the FDA include solidifying leadership with Karim Mikhail at CBER and Michael Davis at CDER—crucial appointments ensuring operational stability amidst past disruptions under former commissioner Marty Makary—and appointing Jared Seehafer as deputy commissioner focusing on AI integration into regulatory processes. Significant financial movements continue highlighting investor interest: Frazier adds over $1 billion targeting small-mid-sized biotech firms while Samsung Biologics secures manufacturing deals emphasizing strategic partnerships' importance globally. Scientific developments also reveal challenges; Silence Therapeutics maintains polycythemia vera leadership despite emerging hurdles while Novo Nordisk halts heart disease studies reflecting complexities validating interleukin-6 as therapeutic targets. AI integration gains momentum transforming operational efficiencies across various functions from R&D to human resources optimizing overall effectiveness within life sciences organizations—a trend poised to reshape people strategy profoundly impacting medical affairs evidenced evaluations enhancing decision-making processes ultimately improving patient outcomes significantly moving forward amidst this dynamic industry landscape filled with opportunities and risks requiring agility and forward-thinking strategies to capitalize on emerging scenarios efficiently and effectively ensuring continued success thriving amidst transformations occurring rapidly around us today, tomorrow, and beyond!Support the show

Why did a failed Novartis drug trial tank Amgen's shares? And how is taxpayer money funding quantum-computing companies? Plus, will people pay $2,000 for a foldable iPhone? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why did a failed Novartis drug trial tank Amgen's shares? And how is taxpayer money funding quantum-computing companies? Plus, will people pay $2,000 for a foldable iPhone? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How do you decide what is the right medication for you after antihistamines are not working to manage your chronic hives? Dr. David Lang, one of the authors of the new chronic urticaria guidelines (still in review), walks through every advanced treatment option the way he would if he had as much time as possible with a patient in his office. Along with Dr. Gupta, they cover the three treatments available when antihistamines are not enough, what each one asks of you week to week, and how to walk into your appointment ready to choose. Dr. Lang's patient guide: Choosing an Advanced Treatment for Chronic Hives  What we cover in our episode about  chronic hives treatment What to think about when choosing a medication: benefit, harm, and burden. Dr. Lang explains why these are three different things, and why the one most patients are never asked about is what a treatment costs them in time, appointments, and schedule. The three advanced options side by side. Omalizumab (Xolair), dupilumab (Dupixent), and remibrutinib (Rhapsido) compared on how often you take them, how fast they work, and what the side effects really are. What the scary side effects actually mean. Dr. Lang walks through the anaphylaxis, cancer, and heart risks tied to omalizumab, and explains how likely each one really is. When blood tests for chronic hives come into the picture. Testing will not tell you why you have hives, but it may hint at which of the three treatments is more likely to work for you. Insurance may choose your starting point. All three treatments are approved for chronic hives, so if your plan covers one over another, that is a reasonable place to start, not a compromise. ************ Made in partnership with The Allergy & Asthma Network. Thanks to Genentech & Novartis for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute for professional medical advice. Always consult with your healthcare provider for any medical concerns.  

On The Kenny & JT Show we welcome in Pro Football Hall of Famer Steve Largent. The 1995 inductee played wide receiver for the Seattle Seahawks from 1976-1989. Steve is in the community this week as part of the Hall's Residency Program presented by Novartis. Our interview is driven by Akron Auto Auction and akronautoauction.com.

Howie and Harlan are joined by cardiologist Aakriti Gupta to discuss advances in minimally invasive heart valve treatment, her work to expand access to cardiovascular care through technology and AI, and a major clinical trial on aortic valve replacement. Howie examines claims that immigration is driving the surge in measles cases; Harlan discusses disappointing trial results for two drugs aimed at preventing cardiovascular disease. Show notes: September 11 9/11 Memorial & Museum: Marking the 25th Anniversary Measles CDC: Measles Cases and Outbreaks" "No evidence linking illegal immigration to measles outbreak, despite Byron Donalds' comment". "Kindergarten Routine Vaccination Rates Continue to Decline" "'Real-life consequences': Pennsylvania Gov. Shapiro, RFK Jr. spar over measles-associated deaths" "Two unvaccinated people die of measles in Pennsylvania" Aakriti Gupta Center for Outcomes Research & Evaluation (CORE) Structural Heart Disease Structural Heart Disease and Interventional Cardiology Heart Valve Disease Open-Heart Surgery Transcatheter aortic valve replacement (TAVR)" "Gender Bias in Choosing Cardiology, Training and Early Career Development" Rajendra Makkar Tia Health Jeff Wessler Heartbeat Health Echocardiogram iCardio.ai AllHeart BELIEVERS trial Failed Drug Trials "Novo Nordisk stops two cardiovascular studies aimed at lowering inflammation" "Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease" Lipoprotein(a) GLP-1 Agonists

Biogen CEO Christopher Viehbacher joins from the Wells Fargo Health Care Conference to discuss the company's drug pipeline and growth outlook. Then, Novartis CEO Vas Narasimhan joins after the company had its third drug trial setback in a week. Plus, we bring you an interview with the CEO of Visa after the company released new data around AI and shopping. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

One of the most unexpected challenges of breast cancer is suddenly needing help with the parts of life you have always managed yourself. Treatment, surgery, and recovery can make everyday responsibilities like working, cooking, cleaning, parenting, driving, and caring for others feel overwhelming or even impossible. Yet knowing you need help and allowing yourself to receive it are two very different things. Dr. Allison Applebaum is a clinical psychologist and caregiving scientist whose work focuses on supporting family caregivers. She is Professor of Geriatrics and Palliative Medicine and Director of the Steven S. Elbaum Family Center for Caregiving at the Icahn School of Medicine at Mount Sinai. In this conversation, she shares practical guidance for women who are struggling to accept support. Together, we explore where to begin, how to identify what help is actually needed, what to delegate, who to ask, and how to communicate those needs clearly. We also discuss how to navigate guilt, preserve a sense of choice and independence, set boundaries when help begins to feel like taking over, and reframe the fear of becoming a burden. Most importantly, this episode gives listeners practical tools, helpful language, and small steps they can use to make asking for and receiving support feel more manageable. To learn more about Dr. Applebaum's work, visit her website and explore her book, Stand By Me: A Guide to Navigating Modern, Meaningful Caregiving, a practical guide for patients, caregivers, and families navigating serious illness. Dr. Applebaum did not receive any funding for participating in this sponsored educational podcast episode. The information shared on Dear Cancer, I'm Beautiful is for educational and informational purposes only and is not intended as medical advice. Always consult your physician or qualified healthcare provider regarding your individual medical care and treatment decisions. The views and opinions expressed by guests are their own and do not necessarily reflect those of Cancer Fashionista. Thank you to Novartis for making this episode of the Signature Series possible.

A pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis, most of which stemmed from the Phase III miss of antisense oligonucleotide therapy pelacarsen. On the latest BioCentury This Week podcast, BioCentury's analysts unpack the fallout for Lp(a) as a cardio target and whether issues with the target, modality or treatment setting contributed to the therapy's lack of efficacy. The analysts also review BioCentury's annual big pharma deals analysis, which found industry's largest players leaning into disruptive platforms such as bispecifics, in vivo CAR Ts, siRNAs, and degraders. In Washington, Steve Usdin reports on most-favored nation drug pricing carve-outs and policy pressure on mid-tier biotechs – plus the conspicuous lack of U.S. biotechs coming to the table -- pays tribute to the late Peter Barton Hutt, the former FDA Chief Counsel who shaped foundational elements of modern FDA law.View full story: https://www.biocentury.com/article/660746 #CardiovascularDisease #DrugPricing #BiotechMA #ClinicalTrials #FDA 0:00 - Introduction 1:23 - Novartis Phase III Fallout18:24 - Annual Pharma Deals Analysis27:42 - MFN Carve-Outs32:39 - Remembering Peter Barton HuttTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Nando Sommerfeldt über einen mächtigen Dämpfer für Novartis, den ETF-Boom bei der DWS Group und Index-Fantasie bei SpaceX. Außerdem geht es um Novartis, Deutsche Bank, Nvidia, Fresenius, Fresenius Medical Care, Amgen, Qualcomm, Amazon, Salesforce, ServiceNow, Intuit, Apple, Bitcoin, Ether, Gold und Genius Sports. Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Ihr wollt dabei sein? Wir verlosen Tickets: Schreibt uns eine Mail an AAA@WELT.de und begründet, warum ihr unbedingt gewinnen solltet. Falls ihr euer Glück nicht dem Zufall überlassen wollt, bekommt ihr mit dem Code „AAAFRIENDS“ satte 50 Prozent Rabatt aufs Ticket – aber nur über diesen Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to the potential of selective estrogen receptor degraders (SERDs) in oncology. The Phase 3 trial results highlight camizestrant's efficacy when combined with CDK4/6 inhibitors, offering a tailored therapeutic strategy for patients with ESR1 mutations. Such advancements in personalized oncology are steering the industry toward more precise treatment paradigms. Complementing this approval, Guardant Health's Guardant360 CDx has been sanctioned as a companion diagnostic tool for camizestrant. The liquid biopsy-based method precisely identifies ESR1 mutations, underscoring the growing reliance on precision diagnostics in cancer management. As precision medicine continues to evolve, integrating diagnostics with therapeutics becomes crucial in achieving optimal patient outcomes. Bristol Myers Squibb has made headlines with its CAR-T cell therapy, arlocabtagene autoleucel, showing efficacy in its Phase 3 trial for GPRC5D-targeted relapsed or refractory multiple myeloma. This advancement reflects the burgeoning application of cell-based treatments in hematological malignancies and signals a shift towards personalized immunotherapy strategies promising improved patient outcomes. On a related note, Brainchild Bio's significant $116 million fundraising initiative aims to advance CAR-T therapies tailored for childhood brain cancers. This development highlights the potential of CAR-T technology beyond hematologic cancers and indicates an intensified focus on pediatric oncology therapeutics. In regulatory news, Shionogi's cefiderocol has gained approval from Australia's Therapeutic Goods Administration (TGA) for combating carbapenem-resistant gram-negative bacterial infections. Cefiderocol addresses critical needs in combating multidrug-resistant pathogens, particularly in urinary tract infections, and highlights ongoing global efforts to tackle antimicrobial resistance. Clinical trials continue to yield promising outcomes. Pharvaris' deucrictibant showcased positive results in its Phase 3 trial for hereditary angioedema by effectively targeting the bradykinin B2 receptor. Novo Nordisk's semaglutide (Wegovy) demonstrated remarkable efficacy in reducing obesity among children during its Phase 3 trials. These results emphasize continued innovation in treating metabolic disorders and rare diseases by leveraging small molecule therapeutics and receptor modulators. Not all developments have been positive. Novartis and Ionis Pharmaceuticals faced setbacks with pelacarsen failing to meet endpoints in a Phase 3 trial aimed at reducing major cardiovascular events despite lowering lipoprotein(a). This underscores the challenges of translating promising biomarkers into effective therapeutic interventions. Regulatory challenges were also observed as American Regent recalled batches of epinephrine due to contamination issues, and Boston Scientific recalled spinal cord implants linked to serious injuries. These instances underscore the importance of stringent quality control and regulatory compliance to ensure patient safety. Meanwhile, Amgen's DLL3-targeted therapy, Imdelltra, achieved an overall survival win in a first-line setting for small cell lung cancer (SCLC), although specific numerical results were not disclosed. This bispecific antibody could set a new standard for early intervention in SCLC, emphasizing the potential of targeted therapies in improving survival rates for aggressive cancers. In other advancements, Roche continues to dominate neurology with top positions in corporate reputation rankings within this therapeutic area. This accolade reflects Roche's commitment to innovation and patient-centric approaches to managing neurological disorders. As these developments unfold across various domains of pharmaceutical innovation and regulation, they collectively signal a dynamic era for the industry marked by rapid scientific progress and evolving treatment strategies. The implications are profound, offering potential improvements in patient outcomes through more targeted therapies while highlighting challenges such as clinical trial failures that necessitate continued diligence in drug development strategies. As these trends unfold, they hold promise for significant advancements in treatment efficacy and safety across various therapeutic areas. Thank you for tuning into Pharma Daily. Stay informed about the latest industry developments as we continue to explore the dynamic landscape of pharmaceutical innovations together.Support the show

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments. https://www.youtube.com/@scalable.capital/videos ASML profitiert von TSMC- und Samsung-Bestellungen. Qualcomm landet Deal mit Amazon. OpenAI und Anthropic wollen günstige Anleihen. VW denkt über Ducati-Verkauf nach. Singapurs Premier verdient 2,8 Mio. $. GE kauft das, was Elon Musk will. Novartis (WKN: 904278) verliert 10% an einem Tag. Zwei Studien-Fails in einer Woche, eine davon aus einer 12 Mrd. $ Übernahme. Pharma-Expertin Helena Smolak erklärt, ob die Pipeline reicht und warum der CEO jetzt unter Druck steht. Mehr von Helena gibt's hier: https://www.linkedin.com/in/helena-smolak/. Zucker hat im August über 20% zugelegt. El Niño, Dürre in Europa und steigende Ölpreise treiben den Preis. Wer profitiert? Adecoagro (WKN: A1H63F), Südzucker (WKN: 729700) oder ein Zucker-ETC (WKN: A0KRK5)? Diesen Podcast vom 09.09.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx's big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis' Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way. 

Apertura a la baja de los principales índices, con la vista puesta en el petróleo. Alberto Roldán, de la Universidad Europea, pone el foco en Novartis, ASML y Scheneider.

P.M. Edition for Sept. 8. OpenAI says it's cracked the Navier-Stokes problem, one of the seven Millennium Prize Problems that are the deepest and most difficult unresolved questions in mathematics. WSJ Science of Success columnist Ben Cohen explains why labs like OpenAI are competing—and spending millions—for such breakthroughs. Plus, a dozen nations are imposing new trade restrictions on Israel over the expansion of settlements in the West Bank. And Smithsonian Secretary Lonnie Bunch III, the first African-American and the first historian to lead the institution, is stepping down after more than a year of tension with President Trump. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Sponsored by Genentech, a member of the Roche Group, and Novartis Pharmaceuticals Corporation. Intended for US Audiences. This information is for general purposes only and is not a substitute for consulting your healthcare provider about food allergy treatment. Brooke and Dr. Ari Zelig have been financially compensated by Genentech and Novartis for their participation in this episode. What does it actually look like to build a full, independent life while managing severe food allergies? In this episode, Whitney is joined by Brooke, a 28-year-old medical student living with food allergies, alongside board certified allergist and immunologist Dr. Ari Zelig, for an honest conversation about navigating everything from childhood birthday parties to dating, travel, restaurants, and everyday situations involving food. Brooke shares how being diagnosed with multiple food allergies forced her to become her own advocate at a young age, and how they ultimately shaped her confidence, relationships, and the physician she hopes to become. Dr. Zelig also discusses the importance of individualized food allergy management and shares information about a treatment option, XOLAIR (omalizumab), an FDA-approved prescription medication for subcutaneous use that can help reduce allergic reactions to multiple foods that may occur after accidental exposure in people with IgE mediated food allergies one year of age and up. While taking XOLAIR you should continue to avoid all foods to which you are allergic. Together, Dr. Zelig and Brooke explore how patients can work with their allergists to create a plan that helps them navigate life while prioritizing safety. Whether you're living with food allergies yourself, supporting someone who is, or simply want to better understand the daily realities, this episode offers practical insights, encouragement, and a reminder that food allergies don't have to define your life. If you or a loved one has been diagnosed with food allergies, talk to your allergist and ask about XOLAIR. You can also find more information at XOLAIR.com. XOLAIR is one of several available treatment options for IgE-mediated food allergy and it may not be appropriate for all patients. What is XOLAIR? XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat food allergy in people 1 year of age and older to reduce allergic reactions that may occur after accidentally eating one or more foods to which you are allergic. While taking XOLAIR you should continue to avoid all foods to which you are allergic. It is not known if XOLAIR is safe and effective in people with food allergy under 1 year of age. XOLAIR should not be used for the emergency treatment of any allergic reactions, including anaphylaxis. What is the most important information I should know about XOLAIR? Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction: • wheezing, shortness of breath, cough, chest tightness, or trouble breathing • low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom” • flushing, itching, hives, or feeling warm • swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after treatment is initiated. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction. Please listen to the end of the episode for additional Important Safety Information. See full Prescribing Information, including Medication Guide, at bit.ly/XOLPI. This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct, or indirect financial interest in products, or services referred to in this episode. Produced by Dear Media.M-US-00032950(v1.0) 9/26 See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, Dr. Kahn discusses the widespread disappointment following Novartis' announcement that its 8,000-patient HORIZON trial of a lipoprotein(a)-lowering drug failed to meet its primary endpoint. The news came as a major surprise and disappointment to patients eagerly awaiting access to this medication. No additional details have been released, and there is not yet a published paper to review. Dr. Kahn discusses the possible reasons the trial failed and what he plans to do moving forward. Other topics include lifestyle factors associated with sudden cardiac arrest, mindfulness for elevated blood pressure, hormone therapy and the female brain during menopause, the risks of off-label testosterone therapy in men, GLP-1 medications and lifespan, Mounjaro and cardiovascular risk, TMAO and brain atrophy, statins and reduced dementia risk, and the connection between adverse pregnancy outcomes and future cardiovascular disease.  Dr. Kahn's new book, Don't Drop Dead, is available in print, audiobook, and Kindle formats on Amazon.  Finally, thanks to WellBean and its amazing bean bars. Use promo code DrKahn15 to save money on your order.

Plus: Amgen has its worst day in more than two decades. And quantum-computing companies rally after U.S. government picks up minority stakes. Imani Moise hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla and Jim Cramer began the show with OpenAI's latest warning about the pace of AI development, with the company's chief scientist saying that “no one is prepared for the consequences of a continued rapid rise in machine intelligence.” The desk also discussed AI beneficiaries, including Qualcomm and Amazon, which announced a new data center infrastructure partnership. After the bell, the anchors highlighted the sharp drop in Novartis shares following three drug trial setbacks.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TD Bank U.S. Vice Chair Jeff Solomon joins with his outlook for the market and the broader economy. Then, Bank of America's Global Head of Commodities Francisco Blanch discusses his expectations for oil prices after fresh strikes in the Middle East over the weekend. Plus, we bring you the details of Novartis' trial setback that has the stock plunging today. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Yemeni Houthis confirm that they hit a Saudi Aramco oil refinery and targeted an air base in retaliation for recent Saudi strikes.Canada's retaliatory tariffs on US goods took effect as scheduled, while US President Trump called for a halt to US sales of Bombardier aircraft.US equity futures trade lower as participants return from holiday; Novartis suffers after key drug misses primary endpoints.USD helped by higher energy prices; JPY continues to firm, helped by strong growth and wage data.Fixed income benchmarks fall, with Gilts underperforming as Amazon (AMZN) files for GBP-denominated debt.Crude complex rises following the Saudi and Yemeni Houthi update.Looking ahead, highlights include US ADP Employment Change Weekly. Speakers include ECB's Elderson, BoE's Bailey, Ramsden, Greene & Taylor. Supply from the US.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

En el episodio de hoy Valentina Orduz y Juan Manuel de los Reyes analizaron una de las semanas más complicadas en la historia de Novartis, que encadenó tres fracasos en sus ensayos clínicos y vio caer su acción cerca de un 12%, poniendo en duda su costosa estrategia de comprar crecimiento justo cuando enfrenta el vencimiento de varias patentes. Revisaron también la nueva escalada comercial entre Canadá y Estados Unidos, con aranceles de represalia por unos $20,000 millones de dólares y el llamado de Trump a boicotear a Bombardier, y lo que todo esto implica para el nearshoring en US. Por último, examinaron cómo TSMC y Samsung se comprometieron a usar la tecnología con las máquinas más avanzadas de ASML.

Araceli de Frutos, asesora del fondo Alhaja Inversiones, repasa el escenario de compañías como Novartis, Infineon, Fresenius y las petroleras.

El director de análisis de Bankinter, Ramón Forcada, analiza la caída de Novartis y nos deja una previa de los resultados de Inditex.

2,6% Zinsen p.a. auf ein unbegrenztes Guthaben mit bis zu fünfmal der gesetzlichen Einlagensicherung*. Auch für Kinder. Das gibt's bei Scalable Capital. Mehr Infos hier. Tesla präsentiert Cybercab ungewohnt unspektakulär und lässt Fragen offen. UiPath und Asana leiden unter KI-Angst. Speicherchips boomen dank GPT-6. AstraZeneca bekommt Brustkrebs-Zulassung. Novartis scheitert mit Herz-Studie. Lululemon crasht. VW einigt sich. Coca-Cola (WKN: 850663) hat 50.000 Freestyle-Automaten, die in Echtzeit Daten nach Atlanta senden. So testet Coke neue Produkte und entdeckt Trends. Dirty Sodas und Mini-Maschinen für Hotels kommen gut an. Aber reicht das bei nem KGV von 26? Xiaomi (WKN: A2JNY1) verkauft ab 2027 E-Autos in Deutschland. Die Autosparte macht schon ein Viertel vom Umsatz. Aber das Handygeschäft bröckelt, weil Speicherchips Marge fressen. Diesen Podcast vom 07.09.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. *Veränderlicher Zins auf unbegrenztes Guthaben. Konditionen sowie Guthabenverteilung auf scalable.capital/tagesgeld. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of pivotal advances and industry dynamics that are shaping the future of healthcare. The U.S. Food and Drug Administration has recently granted approval to Ionis Pharmaceuticals' Zanvastro, a breakthrough in treating Alexander disease. This condition, a rare neurodegenerative disorder caused by mutations in the glial fibrillary acidic protein gene, has historically posed significant treatment challenges. Zanvastro, an antisense oligonucleotide therapy, is notable for being the first of its kind to target this protein, marking a monumental step in precision medicine. The success of this therapy not only opens new avenues for treating Alexander disease but also highlights the potential of antisense technologies to address other rare genetic disorders. Ionis Pharmaceuticals is poised to further explore this innovative therapeutic approach in other neurodegenerative conditions like Angelman syndrome, reinforcing their leadership in targeting rare genetic diseases at the molecular level. Meanwhile, strategic partnerships continue to transform the metabolic disease treatment landscape. The Menarini Group's partnership with Gan & Lee Pharmaceuticals aims to bring the GLP-1 receptor agonist Bofanglutide to European markets. This collaboration underscores the growing emphasis on GLP-1 therapies for managing type 2 diabetes and obesity. With an investment of $72 million upfront and potential milestone payments reaching $771 million, this partnership illustrates the strategic importance of cross-border collaborations in accelerating drug availability and leveraging regional expertise. In parallel, Argo Biopharma has announced promising phase 2 results for its small interfering RNA therapy targeting plasma prekallikrein in hereditary angioedema. This innovative approach offers a prophylactic treatment option for a disease characterized by severe swelling attacks. By harnessing RNA interference mechanisms, Argo Biopharma joins a broader movement within biotech towards gene-silencing technologies that tackle previously challenging conditions. Further emphasizing innovation, Superluminal Medicines has raised $60 million to advance its AI-discovered MC4R-targeting drug for rare obesity conditions. This initiative highlights the transformative potential of artificial intelligence in drug discovery, enabling rapid identification of therapeutic candidates by analyzing extensive datasets and predicting molecular interactions. The focus on rare forms of obesity reflects a broader trend toward personalized medicine, where treatments are increasingly tailored to specific genetic profiles. Regulatory developments also feature prominently with Liquidia Corporation receiving FDA fast track designation for Yutrepia, an inhaled small molecule aimed at treating systemic sclerosis-related Raynaud's phenomenon. This designation will expedite the development and review process for Yutrepia, facilitating quicker access to this potentially life-enhancing treatment for those suffering from autoimmune complications. However, challenges persist within the industry. The FDA issued a warning letter to Fresenius Medical Care over deficiencies related to complaint handling and contamination inspections for sterile injectable products. This action underscores ongoing concerns regarding compliance with safety standards and highlights the critical need for rigorous quality control mechanisms to ensure patient safety. In exploring new therapeutic modalities, psilocybin has shown promise in managing neuropathic pain through preclinical studies. These findings add to the growing body of evidence supporting psychedelics' potential benefits beyond mental health applications, opening new avenues for pain management therapies that could revolutionize treatment protocols. The competitive landscape in weight management sees significant movement with Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vying for dominance in oral GLP-1 receptor agonists. As companies race to develop more patient-friendly formulations, these innovations promise to significantly boost adherence and outcomes in obesity management. Lastly, industry trends reveal an evolving marketing landscape where social media collaborations and strategic partnerships are becoming central to engaging patients and advocating medical conditions. For example, Novartis' partnership with a British Olympian aims to enhance multiple sclerosis advocacy by leveraging influential platforms for patient education and empowerment. These developments paint a picture of a dynamic pharmaceutical and biotech sector characterized by scientific innovation, strategic partnerships, regulatory vigilance, and data-driven approaches. As companies continue to navigate these complexities, their ability to leverage cutting-edge technologies and foster global collaborations will be crucial in delivering transformative health solutions. The industry's focus on precision medicine and novel therapeutic modalities promises significant advancements in patient care and disease management in the years ahead. Thank you for joining us at Pharma Daily—your source for the latest news shaping the world of pharmaceuticals and biotechnology.Support the show

Pablo García, director general de Divacons Alphavalue, pone el foco en Infineon, Novartis, Michelin, STMicroelectronics y EssilorLuxottica.

This episode covers what matters most from ESC Congress 2026:  Heart failure (incl. cardiomyopathies) Primary and secondary prevention ACS & coronary intervention Host: Emer Joyce Guests: Davide Capodanno, Martha Gulati, John McMurray Want to watch that episode? Go to: https://esc365.escardio.org/event/2562   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Martha Gulati has declared to have potential conflicts of interest to report: Merck-Data Monitoring Committee for lipid lowering product. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. John McMurray has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Global Clinical Trial Partners Ltd., WCG Clinical Service, ARMGO Pharmaceuticals, At the Limits Ltd., Hilton Pharmaceuticals, River BioMedics, Novartis, Cytokinetics, Cardurion, Bayer AG, Chugai Pharma UK, Astra Zeneca, AnaCardio, Alnylam, Protherics Medicine Developments Ltd., DalCor Pharmaceuticals, Alkem Metabolics, Canadian Medical and Surgical Knowledge, IMEDIC Pharmaceuticals Micro Labs Ltd., Centrix Healthcare, Eris Lifesciences, Hikma Pharmacueticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceutical, Lupin Pharmaceuticals, Medscape/Heart Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, translational medicine academy, Regeneron, MCI India, Emcure Pharmaceuticals, Biohaven Pharmaceuticals, Kirkland & Ellis Int. Ltd., Tangram Therapeutics, Alphasights Ltd., APTA Therapeutics, Zoll Pharmaceuticals, MSN Lab. Ltd., Omicuris PVT Ltd. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into groundbreaking scientific advancements, crucial regulatory updates, and strategic industry movements that are shaping the future of patient care and drug development. AstraZeneca, in collaboration with Daiichi Sankyo, has achieved a significant milestone with their antibody-drug conjugate, Enhertu, combined with Roche's Perjeta. This combination therapy has recently secured European Union approval for first-line treatment of HER2-positive metastatic breast cancer. The approval highlights the transformative potential of antibody-drug conjugates in treating aggressive breast cancer subtypes. Enhertu targets HER2-positive tumors by delivering cytotoxic agents directly to the cancer cells, thereby minimizing off-target effects and enhancing efficacy. Such innovations underscore the industry's commitment to improving therapeutic outcomes for patients facing complex medical challenges. In another notable development, Novartis has entered into a substantial $3.2 billion licensing agreement with Alteogen, focusing on ALT-B4 hyaluronidase technology. This collaboration emphasizes the growing interest in subcutaneous drug formulations that offer improved patient compliance and convenience compared to traditional intravenous routes. Hyaluronidase helps disperse and absorb subcutaneously injected drugs more efficiently by degrading hyaluronic acid in tissues, thereby enhancing bioavailability and reducing injection volumes. Shifting gears to clinical trial advancements, Hutchmed's combination therapy featuring Tagrisso (osimertinib) and Orpathys (savolitinib) has achieved a Phase 3 success in first-line treatment for MET-overexpressing non-small cell lung cancer. This marks an important stride towards personalized medicine approaches that target specific genetic mutations driving tumor growth. The success of this combination therapy points to a future where targeted treatments become more prevalent in addressing complex oncogenic drivers. In the realm of strategic partnerships, Novacyt and Illumina have embarked on a five-year collaboration focusing on diagnostics and DNA sequencing technologies. This partnership aims to leverage Illumina's genomic sequencing expertise to advance precision medicine efforts in diagnostics, further highlighting the importance of collaborations in overcoming technological hurdles. Meanwhile, in gene therapy developments, NewBiologix and Synastra Biotechnology have joined forces to develop stable recombinant adeno-associated viral cell lines for Duchenne muscular dystrophy therapies. Their partnership aims to address manufacturing challenges associated with gene therapies for rare diseases, potentially accelerating treatment availability for patients in need. Despite these promising advancements, the industry is not without its challenges. Cellares recently announced significant job cuts following the loss of a contract with Bristol Myers Squibb for cell therapy production. Additionally, regulatory scrutiny remains high as evidenced by the UK Medicines and Healthcare products Regulatory Agency's suspension of Amgen's Tavneos amid concerns over trial data integrity. Such developments underscore the critical importance of maintaining rigorous data standards in drug development. Turning our attention to regulatory dynamics, the Trump administration has introduced a new drug pricing model under Medicare, providing weight loss medications at reduced prices for eligible seniors. This initiative involves major players like Eli Lilly and Novo Nordisk and aims to enhance access to obesity treatments for seniors—a move that could signify a shift towards preventive healthcare. On the clinical front, Alnylam Pharmaceuticals' next-generation gene-silencing technology shows promise for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Despite setbacks faced by AstraZeneca and Ionis Pharmaceuticals in similar trials, Alnylam's approach holds potential when used alongside standard treatments. The pharmaceutical sector also sees evolving market dynamics with reverse mergers rising sharply by 1,600% in Q3. This trend rivals traditional IPOs as companies seek alternative routes to liquidity amid fluctuating investor sentiments. Such strategic adaptations reflect the industry's resilience amidst economic uncertainties. In conclusion, these developments paint a picture of an industry dynamically adapting to technological advancements, regulatory changes, and market demands. From innovative drug delivery technologies to strategic partnerships and robust regulatory frameworks, the sector remains committed to advancing precision medicine and improving patient care globally. As these trends continue to unfold, they promise significant implications for drug development processes and therapeutic paradigms across various disease landscapes.Support the show

A.M. Edition for Sept. 1. Apple has a new CEO in the form of John Ternus. WSJ reporter Rolfe Winkler explains how Ternus not only has to follow iconic leader Tim Cook, but also come up with an industry-winning plan for AI. Plus, the SEC asks whether firms promising pre-IPO shares in hot companies actually hold those positions. And President Trump backs the film and TV industry in the hopes that a federal tax credit can save Hollywood. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. The AI Therapist: A WSJ Podcast Series Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Global bond yields are on the rise again, putting rates back at the center of the market conversation. Plus, new trial data from Novartis shows promise for its experimental multiple sclerosis drug. And Pennsylvania Governor Josh Shapiro and Chobani CEO Hamdi Ulukaya join Squawk on the Street following the company's more than $1 billion investment in the state, as Shapiro also discusses his push to rein in the rapid expansion of data centers. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Millions of people live with chronic spontaneous urticaria (CSU) — unpredictable hives and angioedema lasting six weeks or longer with no identifiable trigger. In this episode of the Science of Skin podcast, board-certified dermatologists Dr. Ted Lain and Dr. Michelle Tarbox (Chair, Department of Dermatology, Texas Tech University Health Sciences Center, and host of the Dermosphere podcast) break down what CSU actually is, why it's often misdiagnosed as an allergy, and how it's treated — from first-line antihistamines to omalizumab (Xolair) to the newest option: Rhapsido (remibrutinib), the first oral BTK inhibitor approved for CSU.In this episode, you'll learn:How CSU is diagnosed and why it's classified as a skin disease, not a true allergyThe autoimmune vs. autoallergic subtypes driving chronic hives and angioedemaWhy antihistamine updosing often falls short — and its impact on quality of lifeHow BTK inhibitors like remibrutinib (Rhapsido) work differently than biologics like omalizumabReal patient stories on the toll of chronic hives, misdiagnosis, and finding reliefThis episode is sponsored by Novartis with content independently created by the Science of Skin podcast:Have a question or an idea for a future episode? Email us at inquiry@scienceofskinsummit.com.If you enjoyed this episode, please subscribe, leave a five-star rating, and tell a colleague or friend — word of mouth is how this podcast grows.Topics: chronic spontaneous urticaria, CSU, chronic hives, urticaria treatment, angioedema, BTK inhibitor, remibrutinib, Rhapsido, omalizumab, Xolair, antihistamine-resistant hives, dermatology podcast, autoimmune skin disease